ADA

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

ADA Standards of Care for Overweight and Obesity to Debut at 2025 Scientific Sessions

SECURE-T2D: Automated Insulin Delivery System Reduced A1c in Adults with Type 2 Diabetes

One-Quarter of Adults with Difficult-to-Control T2D have Hypercortisolism, According to New Data

FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use

SURMOUNT-OSA: Tirzepatide Improves Sleep Apnea Symptoms, CV Outcomes in Adults with OSA and Obesity

Pemvidutide Preserves Lean Mass With Weight Loss of Nearly 16%: MOMENTUM Phase 2 Trial

ADA 84th Scientific Sessions: 3 Studies Primary Care Clinicians Should Put on Their Radar

ADA 84th Scientific Sessions Preview: STEP-HFp-EF Trial Data, Tirzepatide for Obesity-Related OSA, Optimizing Diabetes Care in Primary Care

Glycemic Screening in Childhood May Predict Diabetes-Related Complications, According to New Data

New Data Suggest Higher Doses of Oral Semaglutide Beneficial for Management of Type 2 Diabetes

Triple Agonist Retatrutide Associated with Weight Loss of up to 24% in 48-Week Phase 2 Trial

Oral Semaglutide 50 mg May be Effective Option for Obesity Treatment, According to OASIS 1 Study Authors

Oral GLP-1 Agonist Orforglipron Leads to ~15% Mean Body Weight Reduction in Adults with Overweight/Obesity

SURMOUNT-2: Tirzepatide Treatment Leads to Average 15% Weight Loss in Adults with T2D, Obesity

“Triagonist” Therapy for Type 2 Diabetes and Comorbidities to be Previewed at 2023 ADA Scientific Sessions

Flash CGM Increases Time in Range for T2D Patients on Noninsulin Therapies Not at Goal HbA1c

Continuous Glucose Monitoring Linked to Better Glycemic Control, Reduced Hospitalizations in Study of Veterans Health Administration Data

Glycemic Variability with Tirzepatide Significantly Lower vs Degludec as Assessed by CGM

Poorly Controlled T2D Improves with Initiation of rtCGM in Primary Care

Study: AI-powered Intervention Led to Highest Reported Rate of T2D Remission to Date

Semaglutide 2.4 mg Reduces 10-year Risk of Type 2 Diabetes in Patients with Overweight, Obesity

Dulaglutide Improves HbA1c for Youth with Type 2 Diabetes without Change in BMI

Oral Semaglutide in Real-world Study Found Highly Effective for Uncontrolled HbA1c

Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis

Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor Agonists

Younger Age and Higher HbA1c Among Factors Linked to CGM Uptake in New Study

Patients with Diabetes Up to 4-times More Likely to Develop Long COVID-19

Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial

Tirzepatide Slows Renal Decline in T2D Patients with CKD in First Analysis of Dual Agent on Kidney Function